Published in Eur Heart J on September 01, 2015
Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation (XANTUS) | NCT01606995
Italian Registry In the Setting of AF Ablation With Rivaroxaban (IRIS) (IRIS) | NCT04315974
Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs. J Gastroenterol (2017) 1.36
Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Neth Heart J (2017) 0.95
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc (2016) 0.93
Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study. Medicine (Baltimore) (2016) 0.77
Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients? Eur J Clin Pharmacol (2016) 0.76
Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. Adv Ther (2016) 0.75
Assessing generalizability of trial results in general practice. Eur Heart J (2015) 0.75
The year in cardiology 2015: arrhythmias and device therapy. Eur Heart J (2016) 0.75
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States. Int J Clin Pract (2016) 0.75
Managing direct oral anticoagulants in patients undergoing dentoalveolar surgery. Br Dent J (2017) 0.75
Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. J Am Heart Assoc (2016) 0.75
Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice? Arrhythm Electrophysiol Rev (2016) 0.75
Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. J Thromb Thrombolysis (2016) 0.75
DOACs - advances and limitations in real world. Thromb J (2016) 0.75
Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. Cardiovasc Drugs Ther (2016) 0.75
Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study. PLoS One (2016) 0.75
Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. Int J Gen Med (2016) 0.75
Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence. Ther Clin Risk Manag (2017) 0.75
Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. Ther Adv Drug Saf (2016) 0.75
Recent advances in the understanding and management of atrial fibrillation: a focus on stroke prevention. F1000Res (2016) 0.75
Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation. J Thromb Thrombolysis (2016) 0.75
Non vitamin K anticoagulation drugs will win the race. Neth Heart J (2016) 0.75
Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap Adv Gastroenterol (2017) 0.75
Effectiveness and safety of apixaban therapy in daily-care patients with atrial fibrillation: results from the Dresden NOAC Registry. J Thromb Thrombolysis (2017) 0.75
Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients. J Arrhythm (2017) 0.75
A Cross-Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies. J Clin Pharmacol (2017) 0.75
Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol (2017) 0.75
Use of rivaroxaban in patients with stroke. Neurol Sci (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med (2014) 5.44
Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace (2015) 2.67
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood (2014) 1.61
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin (2014) 1.36
Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol (2015) 1.13
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J (2014) 1.12
Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc (2015) 0.99
Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Curr Med Res Opin (2014) 0.94
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag (2014) 0.91
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vasc Health Risk Manag (2014) 0.91
Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study. Europace (2017) 0.75
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy. Clin Cardiol (2016) 0.75